Drug-Associated Delirium Identified in The Food and Drug Administration Adverse Events Reporting System

Download Citation in txt Download Citation in bib Download Citation in ris

Author Info

Adrian Wong Angela Li Kane- Gill Matthew P. Gray Pamela L. Smithburger Seohyun (Claudia) Choi

Corresponding Author

Kane- Gill
University of Pittsburgh Medical Center Presbyterian-Shadyside, Pittsburgh, Pennsylvania

A B S T R A C T

Introduction: Drug toxicity and polypharmacy are major risk factors for delirium, especially in older adult patients with underlying comorbidities. However, numerous case reports have described drugs with a lower suspicion of being deliriogenic. The objective of this study was to identify deliriogenic drugs in the Food and Drug Administration Adverse Events Reporting System (FAERS) to broaden the public knowledge and understanding. Study Design: Retrospective pharmacovigilance evaluation. Methods: FAERS reports from 2004 through 2015 were reviewed for delirium-associated terms, which were utilized to identify drugs most frequently reported to cause delirium. Drugs were categorized as: 1) known to be deliriogenic; 2) potentially deliriogenic; or 3) new potential to be deliriogenic. The 100 most frequently reported drugs were analyzed in reporting odds ratios (ROR). Results: Of the known deliriogenic drugs (n=32), paroxetine (ROR 4.1, CI 4.0-4.3), olanzapine (ROR 3.3, CI 3.2-3.4), and clozapine (ROR 2.9, CI 2.8-3.0) were most reported. Of the potentially deliriogenic drugs (n=54), duloxetine (ROR 3.2, CI 3.1-3.3), varenicline (ROR 3.1, CI 3.0-3.2), and gabapentin (ROR 2.9, CI 2.7-3.0) were most reported. Three drugs were considered to have new potential to be deliriogenic: heparin (ROR 1.5, CI 1.4-1.6), metformin (ROR 1.3, CI 1.3-1.4), and dalfampridine (ROR 1.1, CI 1.1-1.2). Conclusion: The majority of drugs were considered potentially deliriogenic. FAERS can provide postmarketing surveillance data to guide future studies on potentially deliriogenic drugs to guide management of causal agents.

Article Info

Article Type

Research Article

Publication history

Received: Mon 08, Jul 2019
Accepted: Tue 30, Jul 2019
Published: Mon 12, Aug 2019

Copyright

© 2023 Kane- Gill. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.PDR.2019.03.01